Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial–mesenchymal transition

Sorafenib, a pan-protein kinase inhibitor, inhibits the activity of various kinases (like vascular endothelial growth factor, platelet-derived growth factor, and rapidly accelerated fibrosarcoma) and clinically has been used to treat different human cancers. This study investigated its antitumor act...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Chuntao, Liu, Ying, Xue, Lingfei, Zhang, Dong, Zhang, Xiaotong, Su, Jing, Chen, Jiaohong, Li, Xiangke, Wang, Liuxing, Jiao, Shunchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202537/
https://www.ncbi.nlm.nih.gov/pubmed/35800071
http://dx.doi.org/10.1515/biol-2022-0066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202537/
https://www.ncbi.nlm.nih.gov/pubmed/35800071
http://dx.doi.org/10.1515/biol-2022-0066

Ejemplares similares